KRAS and non-small cell lung carcinoma: As a retrospective study for advanced NSCLC receiving immune checkpoint inhibitor monotherapy with at least one oncogenic driver alteration reported, compared with other driver mutations (EGFR, ALK, ROS1), KRAS-mutated patients had the highest ORR to immunotherapy, up to 26% [16].